We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


HTG Molecular Diagnostics Licenses Breast Cancer Marker Patent Portfolio From Merck

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "HTG Molecular Diagnostics Licenses Breast Cancer Marker Patent Portfolio From Merck"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

The Netherlands Cancer Institute is a co-owner of patents and applications in this portfolio.

TJ Johnson, CEO of HTG Molecular Diagnostics, states, "The ability to accurately, quickly, and locally assess a patient's likelihood to have recurrent breast cancer will help improve patient care in the era of personalized medicine. Most breast cancer risk testing is currently run at a few specialty laboratories which often take weeks to return results to treating physicians and nervous patients. As part of our IVD pipeline development, HTG Molecular Diagnostics intends to pursue FDA approvals for tests that provide compelling medical value and to make those standardized tests available to local laboratories via proprietary automation and content. This patent portfolio license from Merck gives HTG access to key intellectual property to bring valuable breast cancer tests to market."